Patents Assigned to Warner-Lambert Company
-
Patent number: 8557835Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.Type: GrantFiled: December 20, 2007Date of Patent: October 15, 2013Assignee: Warner-Lambert Company, LLCInventors: Charles Larry Bisgaier, Roger Schofield Newton
-
Patent number: 8466165Abstract: This invention provides quinazoline compounds of the formula: wherein: R1 is halo; R2 is H or halo; R3 is a) C1-C3 alkyl, optionally substituted by halo; or b) —(CH2)n-morpholino, —(CH2)n-piperidine, —(CH2)n-piperazine, —(CH2)n-piperazine-N(C1-C3 alkyl), —(CH2)n-pyrrolidine, or —(CH2)n-imidazole; n is 1 to 4; R4 is —(CH2)m-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C1-C3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH2, NH(C1-C3 alkyl) or N(C1-C3 alkyl)2; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.Type: GrantFiled: April 5, 2010Date of Patent: June 18, 2013Assignee: Warner-Lambert Company LLCInventors: Stephen Alan Fakhoury, Helen Tsenwhei Lee, Jessica Elizabeth Reed, Kevin Matthew Schlosser, Karen Elaine Sexton, Haile Tecle, Roy Thomas Winters
-
Publication number: 20130131138Abstract: Novel forms of atorvastatin magnesium salt designated Form A, Form B, Form C, Form D, Form E, and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods utilizing the compounds for treatment of hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease are described.Type: ApplicationFiled: January 22, 2013Publication date: May 23, 2013Applicant: Warner-Lambert Company LLCInventors: Jason Albert Leonard, Jonathan Mark Miller
-
Publication number: 20130102675Abstract: A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.Type: ApplicationFiled: December 6, 2012Publication date: April 25, 2013Applicant: Warner-Lambert Company LLCInventor: Warner-Lambert Company LLC
-
Publication number: 20120244167Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: ApplicationFiled: April 27, 2012Publication date: September 27, 2012Applicants: WARNER-LAMBERT COMPANY LLC, AMGEN FREMONT INC.Inventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Publication number: 20120232149Abstract: A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.Type: ApplicationFiled: May 16, 2012Publication date: September 13, 2012Applicant: Warner-Lambert Company LLCInventors: Howard N. Bockbrader, Yun Hyung Cho, Steven Diaz Santiago, Majid Mahjour, Thomas Daniel Reynolds, Pushpa Ganapathi Shao, Zezhi Jesse Shao, Jiansheng Wan
-
Patent number: 8188249Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: GrantFiled: March 29, 2010Date of Patent: May 29, 2012Assignees: Amgen Fremont Inc., Warner-Lambert Company LLCInventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimee Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Publication number: 20120029081Abstract: A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.Type: ApplicationFiled: October 6, 2011Publication date: February 2, 2012Applicant: Warner-Lambert Company LLCInventors: Howard N. Bockbrader, Yun Hyung Cho, Steven Diaz Santiago, Majid Mahjour, Thomas Daniel Reynolds, Pushpa Ganapathi Shao, Zezhi Jesse Shao, Jiansheng Wan
-
Patent number: 7914820Abstract: The present invention relates to novel coating compositions for application to solid dosage forms such as tablets or caplets, solid dosage forms coated with the composition, and methods of preparing said coating compositions.Type: GrantFiled: August 8, 2003Date of Patent: March 29, 2011Assignee: Warner-Lambert Company LLCInventors: Robert Anthony Scott, Dominique Cade, Frederic Hoehn, Ewart Thomas Cole
-
Publication number: 20100247545Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: ApplicationFiled: March 29, 2010Publication date: September 30, 2010Applicants: AMGEN FREMONT INC., WARNER-LAMBERT COMPANY LLCInventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Patent number: 7799823Abstract: The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.Type: GrantFiled: November 7, 2006Date of Patent: September 21, 2010Assignee: Warner-Lambert Company LLCInventors: Stephen Douglas Barrett, Victor Fedij, Lain-Yen Hu, Donna M Iula, Bruce A Lefker, Raj Kumar Raheja, Karen Sexton, Jennifer Ann Van Camp
-
Patent number: 7790197Abstract: A wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof with less than about 5 weight % of an alkaline earth metal salt additive with a disintegrant which provides the atorvastatin with not more than about 3% atorvastatin lactone based on the ratio of lactone peak area compared to the total drug-related peak integrated areas, as well as said wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical compositions.Type: GrantFiled: April 20, 2004Date of Patent: September 7, 2010Assignee: Warner-Lambert Company LLCInventors: Michael B. Fergione, Barbara A. Johnson, Kenneth Craig Waterman
-
Patent number: 7786131Abstract: The present invention relates to pyrimido [5,4-d] pyrimidine compounds of Formula II or a pharmaceutically acceptable salt thereof, wherein Q is and X, E1, E2, E3, R6 and p are as defined herein. The compounds of this invention are irreversible inhibitors of tyrosine kinases and are useful in the treatment of cancer, atherosclerosis, restenosis, endometriosis and psoriasis.Type: GrantFiled: May 20, 2003Date of Patent: August 31, 2010Assignee: Warner-Lambert CompanyInventors: Alexander James Bridges, William Alexander Denny, Ellen Myra Dobrusin, Annette Marian Doherty, David William Fry, Dennis Joseph McNamara, Howard Daniel Hollis Showalter, Jeffrey B. Smaill, Hairong Zhou
-
Patent number: 7772243Abstract: This invention provides quinazoline compounds of the formula: wherein: R1 is halo; R2 is H or halo; R3 is a) C1-C3 alkyl, optionally substituted by halo; or b) —(CH2)n-morpholino, —(CH2)n-piperidine, —(CH2)n-piperazine, —(CH2)n—-piperazine-N(C1-C3 alkyl), —(CH2)n-pyrrolidine, or —(CH2)n-imidazole; n is 1 to 4; R4 is —(CH2)m-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C1-C3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH2, NH(C1-C3 alkyl) or N (C1-C3 alkyl)2; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.Type: GrantFiled: May 5, 2005Date of Patent: August 10, 2010Assignee: Warner-Lambert Company LLCInventors: Stephen Alan Fakhoury, Helen Tsenwhei Lee, Jessica Elizabeth Reed, Kevin Matthew Schlosser, Karen Elaine Sexton, Haile Tecle, Roy Thomas Winters
-
Patent number: 7728113Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: GrantFiled: August 20, 2007Date of Patent: June 1, 2010Assignees: Amgen Fremont Inc., Warner-Lambert Company LLCInventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Patent number: 7674819Abstract: The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.Type: GrantFiled: May 2, 2006Date of Patent: March 9, 2010Assignee: Warner-Lambert Company LLCInventors: Stephen Douglas Barrett, Victor Fedij, Lain-Yen Hu, Donna M. Iula, Bruce A. Lefker, Raj Kumar Raheja, Karen Sexton, Jennifer Ann Van Camp
-
Patent number: 7651009Abstract: The present invention relates to a portable liquid dispensing device. The present invention further relates to a dispensing device equipped with a concealable nozzle which is concealed when not in use and then exposed when it is desirable to spray a liquid such as an oral care product. The liquid dispensing device may be provided with an optional key holder.Type: GrantFiled: June 2, 2005Date of Patent: January 26, 2010Assignee: Warner Lambert Company LLCInventor: Bradford S. Grant
-
Patent number: 7645407Abstract: A method is disclosed for the sealing of hard shell capsules having coaxial body parts which overlap when telescopically joined. Also described is an apparatus to seal the capsules. The method comprises the steps of holding the capsule in a precise and upright position and injecting a quantity of sealing fluid in the overlap of the body parts. An apparatus for performing the method is also disclosed. The apparatus comprises a sealing clamp to hold the capsule in an upright position and means to inject the sealing fluid in the overlap of the body parts.Type: GrantFiled: March 8, 2004Date of Patent: January 12, 2010Assignee: Warner-Lambert Company LLCInventors: Dominique Nicolas Cade, Frederic Hoehn, Philippe Charles Peter, Robert Anthony Scott
-
Patent number: 7592430Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: GrantFiled: September 9, 2004Date of Patent: September 22, 2009Assignees: Amgen Fremont, Warner-Lambert Company, LLCInventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Patent number: RE41920Abstract: The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy.Type: GrantFiled: July 16, 1997Date of Patent: November 9, 2010Assignee: Warner-Lambert Company LLCInventor: Lakhbir Singh